These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 687020)

  • 1. Uremic neuropathy: evidence of middle molecule toxicity.
    Milutinovic J; Babb AL; Eschbach JW; Follette WC; Graefe U; Strand MJ; Scribner BH
    Artif Organs; 1978 Feb; 2(1):45-51. PubMed ID: 687020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Search for the uremic toxin. Decreased motor-nerve conduction velocity and elevated parathyroid hormone in uremia.
    Avram MM; Feinfeld DA; Huatuco AH
    N Engl J Med; 1978 May; 298(18):1000-3. PubMed ID: 205786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors in the dialysis regimen which contribute to alterations in the abnormalities of uremia.
    Lowrie EG; Steinberg SM; Galen MA; Gagneux SA; Lazarus JM; Gottlieb MN; Merrill JP
    Kidney Int; 1976 Nov; 10(5):409-22. PubMed ID: 1003730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma middle molecules in asymptomatic and "sick" uremic patients.
    Asaba H; Bergström J; Fürst P; Johnson C; Yahiel V
    Artif Organs; 1981; 4 Suppl():137-42. PubMed ID: 7295080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myoinositol--a uremic neurotoxin?
    Blumberg A; Esslen E; Bürgi W
    Nephron; 1978; 21(4):186-91. PubMed ID: 683404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Middle molecular weight substances and uremic polyneuropathy.
    Dukanović L; Petrović J; Potić J
    Acta Med Iugosl; 1990; 44(2):117-28. PubMed ID: 2162129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Middle molecule accumulation in uremia: an "extra uremic factor".
    Oulès R; Emond C; Claret G; Branger B; Mion H; Mion C
    Artif Organs; 1981; 4 Suppl():177-83. PubMed ID: 7295089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implications of uremic middle molecules in regular hemodialysis patients.
    Asaba H; Alvestrand A; Fürst P; Bergström J
    Clin Nephrol; 1983 Apr; 19(4):179-87. PubMed ID: 6851254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity of middle molecules: clinical evaluation using a selective filtration artificial kidney.
    Jörstad S; Smeby LC; Wideröe TE
    Artif Organs; 1981; 4 Suppl():98-103. PubMed ID: 7295103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of hemodialysis on endogenous middle molecules in uremic patients.
    Asaba H; Fürst P; Oulés R; Yahiel V; Zimmerman L; Bergström J
    Clin Nephrol; 1979 May; 11(5):257-66. PubMed ID: 455822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood levels of middle molecules and their effects on motor nerve conduction velocity.
    Botella J; Gea T; Sanz-Guajardo D; Criado M; Torres MT; Guardiola J
    Artif Organs; 1981; 4 Suppl():151-5. PubMed ID: 7295082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uremic neuropathy: clinical and neurophysiological investigation of dialysis patients using different chemical membranes.
    Violante F; Lorenzi S; Fusello M
    Eur Neurol; 1985; 24(6):398-404. PubMed ID: 4065159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assay of serum abnormalities in uremic and dialysis patients. Evidence for depletion of vital substances in hemodialysis.
    Quadracci LJ; Cambi V; Christopher TG; Harker LA; Striker GE
    Trans Am Soc Artif Intern Organs; 1971; 17():96-101. PubMed ID: 5158140
    [No Abstract]   [Full Text] [Related]  

  • 14. Chemical analytic approaches to the definition of uremic toxins.
    Furst P; Bergstrom J; Gordon A; Zimmermann L
    Ateneo Parmense Acta Biomed; 1975; 46(5):307-16. PubMed ID: 1232992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of glomerular filtration rate on uremic polyneuropathy.
    Savazzi GM; Migone L; Cambi V
    Clin Nephrol; 1980 Feb; 13(2):64-72. PubMed ID: 6244910
    [No Abstract]   [Full Text] [Related]  

  • 16. An overview of clinical implications of middle molecules and their kinetics in uremia.
    Funck-Brentano JL; Man NK
    Artif Organs; 1981; 4 Suppl():125-32. PubMed ID: 7295078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excess morbidity in patients starting uremia therapy without prior care by a nephrologist.
    Ifudu O; Dawood M; Homel P; Friedman EA
    Am J Kidney Dis; 1996 Dec; 28(6):841-5. PubMed ID: 8957035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can plasma concentration of middle molecules contribute to assessment of adequate dialysis treatment?
    Válek A; Spustová V; Lopot F; Erben J; Dzúrik R
    Artif Organs; 1986 Feb; 10(1):37-44. PubMed ID: 3964096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologic studies in normal and uremic sheep: I. The experimental model.
    Eschbach JW; Adamson JW; Dennis MB
    Kidney Int; 1980 Dec; 18(6):725-31. PubMed ID: 7206457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The middle molecule hypothesis in perspective.
    Babb AL; Ahmad S; Bergström J; Scribner BH
    Am J Kidney Dis; 1981 Jul; 1(1):46-50. PubMed ID: 6277187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.